Efficacy and safety of rituximab treatment in patients with antineutrophil cytoplasmic antibody-associated vasculitides: results from a German registry (GRAID).
|
| Abstract | OBJECTIVE:
Rituximab (RTX) therapy is a treatment option in patients with refractory antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV). We investigated the tolerability and clinical efficacy of RTX in a cohort of patients with refractory AAV. METHODS: Clinical and safety data of patients with AAV treated with RTX were retrospectively assessed from the data of a German national registry. RESULTS: In total, 58 patients were included in this analysis (50/58 with granulomatosis with polyangiitis; 8/58 with microscopic polyangiitis who received at least 1 cycle, 17 patients who received 2 cycles, and 3 patients who received 3 cycles of RTX). Response was classified as complete and partial in 22 (40%) and in 29 cases (52.7%), respectively. Four patients (7.3%) were classified as nonresponders. CONCLUSION: RTX was well tolerated with good clinical efficacy in patients with refractory AAV.
|
|---|---|
| Authors | Petra Roll, Eva Ostermeier, Marion Haubitz, Svjetlana Lovric, Leonore Unger, Julia Holle, Ina Kötter, Jörg C Henes, Raoul Bergner, Andrea Rubbert-Roth, Christof Specker, Hendrik Schulze-Koops, Ulf Müller-Ladner, Martin Fleck, Gerd-Rüdiger Burmester, Falk Hiepe, Stefan Heitmann, Martin Aringer, Rebecca Fischer-Betz, Thomas Dörner, Hans-Peter Tony |
| Journal | The Journal of rheumatology (J Rheumatol) Vol. 39 Issue 11 Pg. 2153-6 (Nov 2012) ISSN: 0315-162X [Print] Canada |
| PMID | 22984269 (Publication Type: Journal Article, Multicenter Study, Research Support, Non-U.S. Gov't) |
| Chemical References |
|
| Topics |
|
Join CureHunter, for free Research Interface BASIC access!
Realize the full power of the drug-disease research graph!